Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients

Mucosal Immunol. 2015 Jan;8(1):127-40. doi: 10.1038/mi.2014.50. Epub 2014 Jul 2.

Abstract

Massive loss of lamina propria CD4(+) T cells, changes in the lymphatic architecture, and altered intestinal epithelial barrier leading to microbial translocation are the common features of HIV-1 infection and are not fully restored under combined antiretroviral therapy (cART). To better understand determinants of gut mucosal restoration, we have performed phenotypic and gene expression analyses of the gut from HIV-infected patients, naive or treated with cART initiated either at the early phase of the primary infection or later during the chronic phase. We found a depletion of T helper type 22 (Th22) and interleukin-17-producing cells in naive patients. These populations, except Th22 cells, were not restored under cART. Regulatory T cells/Th17 ratio was significantly increased in HIV-infected patients and was inversely correlated to the restoration of CD4(+) T cells but not to gut HIV DNA levels. Gene profile analysis of gut mucosal distinguished two groups of patients, which fitted with the timing of cART initiation. In their majority early, but not later treated patients, exhibited conserved intestinal lymphoid structure, epithelial barrier integrity and dendritic cell maturation pathways. Our data demonstrate that early initiation of cART helps to preserve and/or restore lymphoid gut mucosal homeostasis and provide a rationale for initiating cART during the acute phase of HIV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Retroviral Agents / therapeutic use*
  • Cell Differentiation / drug effects
  • Cells, Cultured
  • DNA, Viral / blood
  • Dendritic Cells / drug effects*
  • Dendritic Cells / immunology
  • Dendritic Cells / virology
  • Disease Progression
  • Drug Therapy, Combination
  • Female
  • Gene Expression Profiling
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • Immunity, Mucosal / drug effects
  • Interleukin-22
  • Interleukins / metabolism
  • Intestines / drug effects*
  • Intestines / immunology
  • Intestines / virology
  • Male
  • Middle Aged
  • T-Lymphocytes, Regulatory / drug effects*
  • T-Lymphocytes, Regulatory / immunology
  • T-Lymphocytes, Regulatory / virology
  • Th17 Cells / drug effects*
  • Th17 Cells / immunology
  • Th17 Cells / virology
  • Treatment Outcome

Substances

  • Anti-Retroviral Agents
  • DNA, Viral
  • Interleukins